XNAS
PBYI
Market cap499mUSD
Oct 07, Last price
9.81USD
1D
3.26%
1Q
24.18%
Jan 2017
-68.05%
IPO
-24.54%
Name
Puma Biotechnology Inc
Chart & performance
P/E
16.05
P/S
2.19
EPS
0.61
Div yield, %
—
Shrs. gr., 5y
5.06%
Rev. gr., 5y
0.29%
Revenues
228m
-0.91%
Net income
31m
+2.75%
CFO
42m
+7.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Key people
Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary · since 2010
Maximo Nougues
Chief Financial Officer · since 2018
Alvin Wong
Chief Scientific Officer · since 2021
Douglas Hunt
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer · since 2024
Jeff Ludwig
Chief Commercial Officer · since 2020
Independent Director · since 2022
Independent Director · since 2021
Michael Miller
Independent Director · since 2018
Lead Independent Director · since 2018
Independent Director · since 2015
Independent Director · since 2020
Independent Director · since 2013
IPO date
Mar 21, 2012
Employees
192
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||